Pulmonary infections in transplant recipients

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 3, 2012, Pages

  Küpeli, Elif ^a   Eyüboǧlu, Füsun Ö ^a   Haberal, Mehmet ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

hematopoietic stem cell transplantation; pulmonary infections; solid organ transplantation

Indexed keywords

ACICLOVIR; AMANTADINE; AMINOGLYCOSIDE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEPHALOSPORIN; CIDOFOVIR; COTRIMOXAZOLE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; ECHINOCANDIN; ETHAMBUTOL; FOSCARNET; GANCICLOVIR; ISONIAZID; LINEZOLID; OSELTAMIVIR; POSACONAZOLE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBAVIRIN; RIFABUTIN; RIFAMPICIN; TACROLIMUS; TRIAZOLE; UNINDEXED DRUG; VANCOMYCIN; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTIBIOTIC THERAPY; ATYPICAL MYCOBACTERIOSIS; BACTERIAL PNEUMONIA; BRONCHOSCOPY; CHEMOPROPHYLAXIS; CHEMORADIOTHERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; HEART TRANSPLANTATION; HERPES SIMPLEX; HUMAN; IMMUNE STATUS; INFECTION RISK; INFLUENZA; LUNG ASPERGILLOSIS; LUNG INFECTION; LUNG LAVAGE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBIDITY; MORTALITY; NOCARDIOSIS; NONHUMAN; PARAINFLUENZA VIRUS INFECTION; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SPECIES ENDEMICITY; SURGICAL TECHNIQUE; THORAX RADIOGRAPHY; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; ORGAN TRANSPLANTATION; PNEUMONIA; TUBERCULOSIS, PULMONARY;

EID: 84859214616     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328352104f     Document Type: Review

References (151)

1. Poutsiaka DD, Price LL, Ucuzian A, et al. Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality. Bone Marrow Transplant 2007; 40:63-70. (Pubitemid 47018415)
2. Saubani AO. Respiratory infections following haematopoetic stem cell transplantation. In: Agusti C, Torres A, editors. Pulmonary infection in the immunocompromised patient. 1st ed. UK: Wiley-Blackwell; 2009. pp. 214-215.
3. Oren I, Zuckerman T, Avivi I, et al. Nosocomial outbreak of legionella pneumophila serogroup 3 pneumonia in a new bone marrow transplant unit: evaluation, treatment and control. Bone Marrow Transplant 2002; 30:175-179. (Pubitemid 34993857)
4. Lim do H, Lee J, Lee HG, et al. Pulmonary complications after hematopoietic stem cell transplantation. J Korean Med Sci 2006; 21:406-411.
5. Guidelines for the management of adults with hospital-acquired, ventilator associated, and health-care associated pneumonia. Am J Respir Crit Care Med 2005; 171:88-416.
6. Daly AS, McGeer A, Lipton JH. Systemic nocardiosis following allogeneic bone marrow transplantation. Transpl Infect Dis 2003; 5:16-20. (Pubitemid 36705900)
7. Cordonnier C, Martino R, Trabasso P, et al., European Blood and Marrow Transplant Group Infectious Diseases Working Party. Mycobacterial infection: a difficult and late diagnosis in stem cell transplant recipients. Clin Infect Dis 2004; 38:1229-1236. (Pubitemid 38608563)
8. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-917. (Pubitemid 34229758)
9. Morgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43 (Suppl. 1):S49-S58. (Pubitemid 41038548)
10. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417-1427.
11. Nguyen MH, Leather H, Clancy CJ, et al. Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. Biol Blood Marrow Transplant 2011; 17:1043-1050. This retrospective study looks at the effectiveness of BAL fluid galactomannan (BAL-GM) in diagnosing IPA in 67 patients with hematopoietic stem cell transplantation, The sensitivity of BAL-GM in diagnosing proven or probable IPA was 73 and 67% (10/15) and specificity was 89 and 95%; positive and negative predictive values were 73 and 83%, and 89 and 87%, respectively. It was more sensitive than cytology, BAL fluid culture, transbronchial biopsy or serum galactomannan for diagnosing IPA.
12. Ruhnke M, Böhme A, Buchheidt D, et al., Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Diagnosis of invasive fungal infections in hematology and oncology - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 (Suppl. 2):S141-S148. (Pubitemid 37265301)
13. Lat A, Thompson GR. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist 2011; 4:43-53. This comprehensive review on voriconazole deals with pharmacology and clinical outcomes data of while treating aspergillosis.
14. Arthaus M. Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature. Eur J Med Res 2011; 16:145-152. This review article deals with current state of prophylaxis and treatment of invasive aspergillosis, taking into consideration availability of newer antifungal agents posaconazole and caspofungin.
15. Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060-1068. (Pubitemid 44631109)
16. Klont RR, Mennink-Kersten MA, Ruegebrink D, et al. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis 2006; 43:e23-e25.
17. Matt P, Bernet F, Habicht J, et al. Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. Chest 2004; 126:1783-1788. (Pubitemid 39643980)
18. De Castro N, Neuville S, Sarfati C, et al. Occurrence of pneumocystis jirovecii pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 2005; 36:879-883. (Pubitemid 41655614)
19. Styczynski J, Reusser P, Einsele H, et al. Management of hSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43:757-770.
20. Alexander BT, Hladnik LM, Augustin KM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy 2010; 30:554-561. This retrospective study describes the clinical outcomes of HSCT recipients who received adjunctive CMV-IVIG for probable or proven CMV disease. Analysis suggests that the factors associated with mortality are the need for intubation and earlier onset of CMV disease after HSCT. Treatment with CMV-IVIG appears to be well tolerated in HSCT recipients.
21. Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 42 (Suppl. 1):S70-S72.
22. Ljungman P, de la Camara R, Cordonnier C, et al. Management of cMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. European Conference on Infections in Leukemia. Bone Marrow Transplant 2008; 42:227-240.
23. Lee I, Barton TD. Viral respiratory tract infections in transplant patients: epidemiology, recognition and management. Drugs 2007; 67:1411-1427. (Pubitemid 47026391)
24. Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004; 170:22-48. (Pubitemid 38997749)
25. Griffith DE, Aksamit T, Brown-Elliott BA, et al., ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367-416. (Pubitemid 46271561)
26. Dharnidharka VR, Agodoa LY, Abbott KC. Risk factors for hospitalization for bacterial or viral infection in renal transplant recipients - an analysis of USRDS data. Am J Transplant 2007; 7:653-661. (Pubitemid 46376457)
27. Arya B, Hussian S, Hariharan S. Rhodococcus equi pneumonia in a renal transplant patient: a case report and review of literature. Clin Transplant 2004; 18:748-752. (Pubitemid 39496993)
28. De Boer MG, Kroon FP, le Cessie S, et al. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis 2011; 13:559-569. A retrospective study was performed to identify risk factors for PCP in kidney transplant recipients and to define parameters for use in clinical prophylaxis guidelines. It revealed that chemoprophylaxis in the first 6 months for all renal transplant patients - and during the first year after transplantation for patients greater than 55 years of age or those treated for rejection - would result in very low PCP incidence and optimal avoidance of TMP-SMX toxicity.
29. Fortun J, Martin-Davila P, Pascual J, et al. Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis 2010; 12:397-405. This prospective study evaluated the possible association between infection and immunosuppression regimens in 1398 renal transplant recipients. The study concluded that the use of sirolimus as maintenance therapy in kidney recipients is associated with a low rate of CMV infection and with a higher risk of surgical site infection.
30. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101-1111. TRANSNET prospectively surveyed and identified 1208 invasive fungal infections among 1063 organ transplant recipients. The most common were candidiasis, aspergillosis, and cryptococcosis, median time to onset being 103, 184, and 575 days, respectively.
31. Zhang XF, Lv Y, Xue WJ, et al. Mycobacterium tuberculosis infection insolid organ transplant recipients: experience from a single center in China. Transplant Proc 2008; 40:1382-1385. (Pubitemid 351853211)
32. Gasink LB, Blumberg EA. Bacterial and mycobacterial pneumonia in transplant recipients. Clin Chest Med 2005; 26:647-659. (Pubitemid 41563264)
33. Sánchez-Lázaro IJ, Almenar L, Blanes M. Timing, etiology, and location of first infection in first year after heart transplantation. Transplant Proc 2010; 42:3017-3019. This prospective study involving 604 heart transplant recipients suggests that nearly half of the patients experience a significant infection during the first year after transplantation. Early onset infections occur in the ICUs and are caused by nosocomial organisms; late-onset infections are of more varied etiology and preferentially affect the skin and genitourinary tract.
34. Refaat M, McNamara D, Teuteberg J. Successful cidofovir treatment in an adult heart transplant recipient with severe adenovirus pneumonia. J Heart Lung Transplant 2008; 27:699-700.
35. Cunha BA, Eisenstein LE, Dillard T. Herpes simplex virus (HSV) pneumonia in a heart transplant: diagnosis and therapy. Lung 2007; 36:72-78. (Pubitemid 46110849)
36. Lopez de Castilla D, Schluger NW. Tuberculosis following solid organ transplantation. Transpl Infect Dis 2010; 12:106-112. This retrospective study involving 4925 solid-organ transplantation recipients concludes that the incidence of TB in transplant recipients is much higher than the overall background incidence in the USA; non-Caucasian and renal transplant recipients are at higher risk likely because of latent disease.
37. Goldberg HJ, Deykin A. Advances in lung transplantation for patients who have cystic fibrosis. Clin Chest Med 2007; 28:445-457. (Pubitemid 46654474)
38. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001; 33:1397-1405. (Pubitemid 32955195)
39. Poonyagariyagorn HK, Gershman A, Avery R. Challenges in the diagnosis and management of nocardia infections in lung transplant recipients. Transpl Infect Dis 2008; 10:403-408.
40. Lease ED, Zaas DW. Update on infectious complications following lung transplantation. Curr Opin Pulm Med 2011; 17:206-209. Pulmonary infection is the major complication following lung transplantation. This review provides more information on CMV prophylaxis and treatment, epidemiology of fungal infection, and the role of both infections on the development of bronchiolitis obliterans syndrome.
41. Solé A, Morant P, Salavert M. Aspergillus infections in lung transplant recipients: risk factors and outcome. Lung Transplant Group. Clin Microbiol Infect 2005; 11:359-365. (Pubitemid 40575818)
42. Solidoro P, Delsedime L, Bergallo M, et al. Combined prophylaxis decreases incidence of CMV-associated pneumonia after lung transplantation. Transplant Proc 2009; 41:1347-1348.
43. Vu DL, Bridevaux PO, Aubert JD, et al. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant 2011; 11:1071-1078. Thirty-four studies examining relationship between viral respiratory infection and complications were reviewed. It confirmed a causal relationship between respiratory viruses and symptoms, but not with acute lung rejection.
44. Aduen JF, Hellinger WC, Kramer D, et al. Spectrum of pneumonia in the current era of liver transplantation and its effect on survival. Mayo Clin Proc 2005; 80:1303-1306. (Pubitemid 41395963)
45. Shi SH, Kong HS, Jia CK, et al. Risk factors for pneumonia caused by multidrug-resistant Gram-negative bacilli among liver recipients. Clin Transplant 2010; 24:758-765.
46. Weiss E, Dahmani S, Bert F, et al. Early-onset pneumonia after liver transplantation: microbiological findings and therapeutic consequences. Liver Transpl 2010; 16:1178-1185. The study prospectively analyzed microbiological findings, associated factors, and optimal antibiotic regimens for early onset, hospital-acquired pneumonia (E-HAP) after 148 liver transplantation. The outcome was influenced by lactatemia, postoperative SAPS II score and requirement for vasopressors and mechanical ventilation requirements.
47. Obed A, Schnitzbauer AA, Bein T, et al. Fatal pneumonia caused by Panton-Valentine Leucocidine-positive methicillin-resistant Staphylococcus aureus (PVL-MRSA) transmitted from a healthy donor in living-donor liver transplantation. Transplantation 2006; 81:121-124. (Pubitemid 43122159)
48. Gudiol C, Garcia-Vidal C, et al. Clinical features and outcomes of Legionnaires'disease in solid organ transplant recipients. Transpl Infect Dis 2009; 11:78-82.
49. Almaslmani M, Derbala MF, Albozom I, et al. Bronchiolitis obliterans organizing pneumonia associated with Pneumocystis jirovecii infection in orthotopic liver transplantation. Transpl Infect Dis 2008; 10:339-342.
50. Caner A, Döşkaya M, Karasu Z, et al. Incidence and diagnosis of active toxoplasma infection among liver transplant recipients in Western Turkey. Liver Transpl 2008; 14:1526-1532.
51. Liu X, Ling Z, Li L, et al. Invasive fungal infections in liver transplantation. Int J Infect Dis 2011; 15:e298-e304. The review highlights the types of invasive fungal infection, their risk factors, diagnosis, prophylaxis, and treatment after liver transplantation.
52. Silveira FP, Husain S, Kwak EJ, et al. Cryptococcosis in liver and kidney transplant recipients receiving antithymocyte globulin or alemtuzumab. Transpl Infect Dis 2007; 9:22-27.
53. Ison MG, Fishman JA. Cytomegalovirus pneumonia intransplant recipients. Clin Chest Med 2005; 26:691-705.
54. WHO (cited 3/9/2011). Available from http://gamapserver.who.int/gho/ interactive-charts/MDG6-TB/atlas.htlm?indicator=i0&date=2008.
55. Subramanian A, Dorman S. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl. 4):S57-S62.
56. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27:1266-1277. (Pubitemid 29242482)
57. Currie AC, Knight SR, Morris PJ. Tuberculosis in renal transplant recipients: the evidence for prophylaxis. Transplantation 2010; 90:695-704. This study review focuses on the epidemiology of TB in renal transplant recipients and appraises the literature on INH prophylaxis. It supports INH prophylaxis in this group of patients at risk of active infection.
58. Budak-Alpdogan T, Tangun Y, Kalayoglu-Besisik S, et al. The frequency of tuberculosis in adult allogeneic stem cell transplant recipients in Turkey. Biol Blood Marrow Transplant 2000; 6:370-374.
59. Navari RM, Sullivan KM, Springmeyer SC, et al. Mycobacterial infections in marrow transplant patients. Transplantation 1983; 36:509-513. (Pubitemid 14231240)
60. Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009; 48:1657-1665.
61. Arslan H, Ergin F, Öner Eyüboǧlu F, et al. Tuberculosis in renal transplant recipients. Transplant Proc 2003; 35:2670-2681.
62. Aguado JM, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48:1276-1284.
63. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37:88-99. This meta-analysis to compare the accuracy of the QuantiFERON-TB Gold In-Tube (QFT-G-IT) and the T-SPOT TB assays with the tuberculin skin test (TST) for the diagnosis of latent Mycobacterium tuberculosis infection (LTBI). IGRAs may have a relative advantage over the TST in detecting LTBI and allow the exclusion of M. tuberculosis infection with higher reliability.
64. Interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2007; 33(ACS-10):1-18.
65. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33:956-973.
66. Vachharajani T, Abreo K, Phadke A, et al. Diagnosis and treatment of tuberculosis in hemodialysis and renal transplant patients. Am J Nephrol 2000; 20:273-277.
67. Al-Sulaiman MH, Dhar JM, al-Khader AA. Successful use of rifampicin in the treatment of tuberculosis in renal transplant patients immunosuppressed with cyclosporine. Transplantation 1990; 50:597-598. (Pubitemid 20358530)
68. Ngo BT, Pascoe M, Khan D. Drug interaction between rifampicin and sirolimus in transplant patients. Saudi J Kidney Dis Transpl 2011; 22:112-115. The article reports two cases of drug interaction between rifampicin and sirolimus in renal transplant recipients with TB. The dose of sirolimus had to be increased, by five to sixfold to maintain proper therapeutic levels and for optimal outcome.
69. Doucette K, Fishman JA. Nontuberculous mycobacterial infection in hematopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 2004; 38:1428-1439. (Pubitemid 38678611)
70. Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 2003; 16:319-354. (Pubitemid 36519815)
71. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367-416.
72. Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 1999; 160:1611-1616.
73. Dorman S, Subramanian A, AST Infectious Diseases Community of Practice. Nontuberculous mycobacteria in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl. 4):S63-S69.
74. Patel R, Roberts GD, Keating MR, Paya CV. Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis 1994; 19:263-273. (Pubitemid 24258925)
75. Zaidi S, Elidemir O, Heinle JS, et al. Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis 2009; 11:243-248.
76. Garrison AP, Morris MI, Doblecki Lewis S, et al. Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature. Transpl Infect Dis 2009; 11:541-548.
77. Baughman RP, Lower EE. Diagnosis of pneumonia in immunocompromised patient. In: Agusti C, Torres A, editors. Pulmonary infection in the immunocompromised patient. 1st ed. UK: Wiley-Blackwell; 2009. p. 78.
78. Cervera C, Agustí C, Angeles Marcos M, et al. Microbiologic features and outcome of pneumonia in transplanted patients. Diagn Microbiol Infect Dis 2006; 55:47-54.
79. Bonatti H, Pruett TL, Brandacher G, et al. Pneumonia in solid organ recipients: spectrum of pathogens in 217 episodes. Transplant Proc 2009; 41:371-374.
80. Hofmeister CC, Czerlanis C, Forsythe S, et al. Retrospective utility of bronchoscopy after hematopoietic stem cell transplant. Bone Marrow Transplant 2006; 38:693-698. (Pubitemid 44669685)
81. Dunagan DP, Baker AM, Hurd DD, Haponik EF. Bronchoscopic evaluation of pulmonary infiltrates following bone marrow transplantation. Chest 1997; 111:135-141. (Pubitemid 27043620)
82. Shannon VR, Andersson BS, Lei X, et al. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45:647-655. The study retrospectively reviewed 501 consecutive, adult, nonintubated patients who underwent 598 BALs for evaluation of new infiltrates during the first 100 days following HSCT to determine outcomes difference between early versus late intervention. The study concludes that early bronchoscopy in this setting is associated with higher diagnostic yields and may favorably impact survival.
83. Patel NR, Lee PS, Kim JH, et al. The influence of diagnostic bronchoscopy on clinical outcomes comparing adult autologous and allogeneic bone marrow transplant patients. Chest 2005; 127:1388-1396. (Pubitemid 46224306)
84. Kupeli E, Akcay S, Ulubay G, et al. Diagnostic utility of flexible bronchoscopy in recipients of solid organ transplants. Transplant Proc 2011; 43:543-546. A retrospective study evaluated the diagnostic utility of flexible bronchoscopy in 61 SOT recipients with suspected pulmonary complications. An infection was the most common indication for flexible bronchoscopy and identified causative organism in more than 30% of patients.
85. Huaringa AJ, Leyva FJ, Signes-Costa J, et al. Bronchoalveolar lavage in the diagnosis of pulmonary complications of bone marrow transplant patients. Bone Marrow Transplant 2000; 25:975-979. (Pubitemid 30255731)
86. Joos L, Chhajed PN, Wallner J, et al. Pulmonary infections diagnosed by BAL: a 12-year experience in 1066 immunosuppressant patients. Respir Med 2007; 101:93-97. (Pubitemid 44835237)
87. Prasoon J, Sunder S, Yvonne M, et al. Role of bronchoscopy in immunosuppressant patients with lung infiltrates. Chest 2004; 125:712-722.
88. Tamm M, Traenkle P, Grilli B, et al. Pulmonary cytomegalovirus infection in immunosuppressant patients. Chest 2001; 119:838-843. (Pubitemid 32197657)
89. Van Kraaij MG, van Elden LJ, van Loon AM, et al. Frequent detection of respiratory viruses in adult recipients of stem cell transplants with the use of real-time polymerase chain reaction, compared with viral culture. Clin Infect Dis 2005; 40:662-669. (Pubitemid 40381338)
90. Soubani AO, Qureshi MA. Invasive pulmonary aspergillosis following bone marrow transplantation: risk factors and diagnostic aspect. Haematologia (Budap) 2002; 32:427-437. (Pubitemid 36665352)
91. Nusair S, Kramer MR. The role of fibre-optic bronchoscopy in solid organ, transplant patients with pulmonary infections. Respir Med 1999; 93:621-629. (Pubitemid 29476251)
92. Cazzadori A, Di Perri G, Todeschini G, et al. Transbronchial biopsy in the diagnosis of pulmonary infiltrates in immunosuppressant patients. Chest 1995; 107:101-106.
93. Sternberg RI, Baughman RP, Dohn MN, et al. Utility of bronchoalveolar lavage in assessing pneumonia in immunosuppressed renal transplant recipients. Am J Med 1993; 95:358-364. (Pubitemid 23303063)
94. Sreeniwas R, Schulman LL, Berkman YM, et al. Opportunistic bronchopulmonary infections after lung transplantation: clinical and radiographic findings. Radiology 1996; 200:349-356. (Pubitemid 26249882)
95. Schulman LL, Smith CR, Drusin R, et al. Utility of airway endoscopy in the diagnosis of respiratory complications of cardiac transplantation. Chest 1988; 93:960-967.
96. Verdaguer V, Walsh TJ, Hope W, et al. Galactomannan antigen detection in the diagnosis of invasive aspergillosis. Expert Rev Mol Diagn 2007; 7:21-32. (Pubitemid 46114704)
97. Husain S, Paterson DL, Studer SM, et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation 2007; 83:1330-1336. (Pubitemid 46800308)
98. Wallace RH, Kolbe J. Fiberoptic bronchoscopy and bronchoalveolar lavage in the investigation of the immunosuppressant lung. N Z Med J 1992; 105:215-217.
99. American Thoracic Society Workshop. Rapid diagnostic tests for tuberculosis. Am J Respir Crit Care Med 1997; 155:1804-1814.
100. Kramer MR, Berkman N, Mintz B, et al. The role of open lung biopsy in the management and outcome of patients with diffuse lung disease. Ann Thorac Surg 1998; 65:198-202. (Pubitemid 28105892)
101. Agoglia L, Balbi E, Halpern M, Roma J, et al. Tuberculosis in Liver Transplant Recipients: Prophylaxis in an Endemic Area. Transplant Proc 2011; 43:199-202.
102. Ahmad S, Shlobin OA, Nathan SD. Pulmonary Complications of lung Transplantation. Chest 2011; 139:402-411.
103. Akindipe OA, Fernandez-Bussy S, Staples ED, Baz MA. Discrepancies between clinical and autopsy diagnoses in lung transplant recipients. Clin Transplant 2010; 24:610-614.
104. Alexander BT, Hladnik LM, Augustin KM, et al. Use of cytomegalovirus intravenous immune globulin for the adjunctive treatment of cytomegalovirus in hematopoietic stem cell transplant recipients. Pharmacotherapy 2010; 30:554-561.
105. Arthaus M. Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature. Eur J Med Res 2011; 16:145-152. [14]
106. Chambers DC, Hodge S, Hodge G, Yerkovich ST, et al. A novel approach tothe assessment of lymphocytic bronchiolitis after Lung transplantation- transbronchial brush. J Heart Lung Transplant 2011; 30:544-551.
107. Chen G, Zhang Z, Gu J, Qiu J, et al. Incidence and Risk Factors for Pulmonary Mycosis in Kidney Transplantation. Transplant Proc 2010; 42:4094-4098.
108. Cohen J, Singer P, Raviv Y, Bakal I, et al. Outcome of lung transplant recipients requiring readmission to the intensive care unit. J Heart Lung Transplant 2011; 30:54-58.
109. Cordonnier C, Pautas C, Kuentz M, Maitre B, et al. Early pneumonia after allogenic stem cell transplantation. Rev Mal Respir 2010; 27:77-88.
110. Costa C, Bergallo M, Astegiano S, Sidoti F, et al. Detection of human rhinoviruses in the lower respiratory tract of lung transplant recipients. Arch Virol 2011; 156:1439-1443.
111. Costa C, Curtoni A, Bergallo M, Solidoro P, et al. Quantitative detection of hHV-6 and HHV-7 in transbronchial biopsies from lung transplant recipients. New Microbiol 2011; 34:275-280.
112. Currie AC, Knight SR, Morris PJ. Tuberculosis in renal transplant recipients: the evidence for prophylaxis. Transplantation 2010; 90:695-704. [57]
113. Davis CS, Deburghgraeve CR, Yong S, Parada JP, et al. Challenges in the Diagnosis of 2009 H1N1 in a Lung Transplant Patient and the Long-Term Implications for Prevention and Treatment: A Case Report. Transplant Proc 2010; 42:4295-4299.
114. De Boer MG, Kroon FP, le Cessie S, et al. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis 2011; 13:559-569. [28]
115. de la Morena MP, Bravos MD, Prado RF, Roel MD, et al. Chronic Kidney Disease After Lung Transplantation: Incidence, Risk Factors, and Treatment. Transplant Proc 2010; 42:3217-3219.
116. Della Gasperina D, Tozzi M, Astuti N, Balsamo ML, et al. Pulmonary Tuberculosis in an HIV- and Hepatitis C Virus-Coinfected Kidney-Pancreas Transplant Recipient: A Case Report. Transplant Proc 2011; 43:1206-1209.
117. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37:88-99. [63]
118. Fortun J, Martin-Davila P, Pascual J, et al. Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis 2010; 12:397-405. [29]
119. Garofano R, Rodriguez MA, Prados MC, Moriana C, et al. Cases of swine Flu in Kidney Transplant Recipients in our Hospital. Transplant Proc 2010; 42:3141-3142.
120. Grossi PA, Gasperina DD, Barchiesi F, Biancofiore G, et al. Italian Guidelines for Diagnosis, Prevention, and Treatment of Invasive Fungal Infections in Solid Organ Transplant Recipients. Transplant Proc 2011; 43:2463-2471.
121. Hoyo I, Linares L, Cervera C, Almela M, et al. Epidemiology of pneumonia in Kidney Transplantation. Transplant Proc 2010; 42:2938-2940.
122. Huang HC, Weigt SS, Derhovanessian A, Palchevskiy V, et al. Non-tuberculous mycobacterium infection after lung transplantation is associated with increased mortality. J Heart Lung Transplant 2011; 30:790-798.
123. Kovats Z, Sutto Z, Murakozy G, Bohacs A, et al. Airway Pathogens During the First Year after Lung Transplantation: A Single-Center Experience. Transplant Proc 2011; 43:1290-1291.
124. Kugler C, Gottlieb J, Dierich M, Haverich A, et al. Significance of patient self-monitoring for long-term outcomes after lung transplantation. Clin Transplant 2010; 24:709-716.
125. Kupeli E, Akcay S, Ulubay G, et al. Diagnostic utility of flexible bronchoscopy in recipients of solid organ transplants. Transplant Proc 2011; 43:543-546. [84]
126. Kupeli E, Akcay S, Ulubay G, Ozyurek BA, et al. Diagnostic Utility of Flexible Bronchoscopy in Recipients of Solid Organ Transplants. Transplant Proc 2011; 43:543-546.
127. Kupeli E, Ulubay G, Colak T, Ozdemirel TS, et al. Pulmonary Complications in Renal Recipients After Transplantation. Transplant Proc 2011; 43:551-553.
128. Lat A, Thompson GR. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist 2011; 4:43-53. [13]
129. Lease ED, Zaas DW. Update on infectious complications following lung transplantation. Curr Opin Pulm Med 2011; 17:206-209. [40]
130. Lease ED, Zaas DW. Update on infectious complications following lung transplantation. Curr Opin Pulm Med 2011; 17:206-209.
131. Liu X, Ling Z, Li L, et al. Invasive fungal infections in liver transplantation. Int J Infect Dis 2011; 15:e298-e304. [51]
132. Lopez de Castilla D, Schluger NW. Tuberculosis following solid organ transplantation. Transpl Infect Dis 2010; 12:106-112. [36]
133. Low CY, Kee T, Chan KP, Oon LLE, et al. Pandemic (H1N1) 2009 Infection in Adult Solid Organ Transplant Recipients in Singapore. Transplantation 2010; 90:1016-1021.
134. Luong ML, Morrissey O, Husain S. Assessment of infection risks prior to lung transplantation. Curr Opin Infect Dis 2010; 23:578-583.
135. Machuca TN, Camargo SM, Schio SM, Lobato V, et al. Lung Transplantation for Patients Older Than 65 Years: Is It a Feasible Option. Transplant Proc 2011; 43:233-235.
136. Manuel O, Humar A, Berutto C, Ely L, et al. Low-dose intradermal versus intramuscular trivalent in activated seasonal influenza vaccine in lung transplant recipients. J Heart Lung Transplant 2011; 30:679-684.
137. Morales P, Gil A, Santos M. Mycobacterium abscessus Infection inTransplant Recipients. Transplant Proc 2010; 42:3058-3060.
138. Ngo BT, Pascoe M, Khan D. Drug interaction between rifampicin and sirolimus in transplant patients. Saudi J Kidney Dis Transpl 2011; 22:112-115. [68]
139. Nguyen MH, Leather H, Clancy CJ, et al. Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. Biol Blood Marrow Transplant 2011; 17:1043-1050. [11]
140. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101-1111. [30]
141. Park JW, Kim JH, Kim WB, Han HJ, et al. Invasive Pulmonary Aspergillosis After Living Donor Liver Transplantation Should Be Eradicated or Not A Case Report. Transplant Proc 2011; 43:2428-2430.
142. Sánchez-Lázaro IJ, Almenar L, Blanes M. Timing, etiology, and location of first infection in first year after heart transplantation. Transplant Proc 2010; 42:3017-3019. [33]
143. Sanchez-Lazaro IJ, Almenar L, Blanes M, Martinez-Dolz L, et al. Timing, Etiology, and Location of First Infection in First Year After Heart Transplantation. Transplant Proc 2010; 42:3017-3019.
144. Shannon VR, Andersson BS, Lei X, et al. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45:647-655. [82]
145. Sims KD, Blumberg EA. Common Infections in the Lung Transplant Recipient. Clin Chest Med 2011; 32:327-341.
146. Smud A, Nagel CB, Madsen E, Rial MD, et al. Pandemic Influenza A/H1N1 Virus Infection in Solid Organ Transplant Recipients: A Multicenter Study. Transplantation 2010; 90:1458-1462.
147. Vikram HR, Dosanjh A, Blair JE. Coccidioidomycosis and Lung Transplantation. Transplantation 2011; 92:717-721.
148. Vu DL, Bridevaux PO, Aubert JD, et al. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant 2011; 11:1071-1078. [43]
149. Vu DL, Bridevaux PO, Aubert JD, Soccal PM, et al. Respiratory Viruses in Lung Transplant Recipients: A Critical Review and Pooled Analysis of Clinical Studies. Am J Transplant 2011; 11:1071-1078.
150. Weiss E, Dahmani S, Bert F, et al. Early-onset pneumonia after liver transplantation: microbiological findings and therapeutic consequences. Liver Transpl 2010; 16:1178-1185. [46]
151. Zamora MR, Budev M, Rolfe M, Gottlieb J, et al. RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus. Am J Respir Crit Care Med 2011; 183:531-538.